Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - PR Newswire
Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation PR Newswire
Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium - The Manila Times
Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium The Manila Times